Effects of SGLT2 Inhibitors on Left ventricular dimensions and function in non-diabetic patients with heart failure reduced ejection fraction due to non-ischemic and ischemic cardiomyopathy in non-acute coronary syndrome setting

Dr Nagpal Raghav Radhakrishan0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年3月6日

试验速览

暂无简介。

•LVEF equal to or less than 45%
•More than 3 months from ACS event
•Ischemic Cardiomyopathy patients who have undergone complete revascularization in the form of percutaneous coronary intervention or surgery more than 3 months prior to inclusion in the study
•Creatinine clearance of less than equal to 30 ml per min per m2
•Patients on optimal heart failure therapy, beta blockers ARB ACE inhibitors aldosterone antagonists and or diuretics if tolerated

•1) Diabetes Mellitus
•2) Recent ACS, <3 months
•3) Ischemic cardiomyopathy patients who have not undergone complete revascularization
•4) Coronary Revascularization ( percutaneous coronary revascularization or coronary artery bypass grafting) or valvular repair/replacement within 3 months prior to enrolment
•5)severe infection
•6) serious liver or renal functional failure eGFR < 30 ml/min/m2
•7) alcohol dependency or use of illicit drugs
•8) pregnant or breastfeeding, possibly pregnant or planning to become pregnant in the study period (female patients only)
•9) urinary tract or genital infection
•10) history of hypersensitivity to the study drugs
•11) severe ketosis, diabetic coma or precoma
•12) ongoing or past history of pancreatitis
•13) heart failure due to restrictive cardiomyopathy, active myocarditis, constrictive pericarditis, hypertrophic (obstructive) cardiomyopathy or uncorrected primary valvular disease
•14) symptomatic bradycardia or second or third degree heart block without a pacemaker

发起方

Dr Nagpal Raghav Radhakrishan